Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.60 |
| ▸ | CES1 | P23141 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704195 | 1.00 | CES2 (0.60) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL10814548 | 1.00 | CES2 (0.60) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL10131971 | 0.82 | CES2 (0.58) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL10131977 | 0.82 | CES2 (0.58) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL5670381 | 0.81 | CES2 (0.62) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL11230378 | 0.81 | MAPT (0.53) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL9242877 | 0.81 | MAPT (0.53) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL11371271 | 0.81 | CES2 (0.62) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL5670379 | 0.81 | CES2 (0.62) | CES2CES1MAPTSMN1; SMN2POLB | |
| SCHEMBL7871754 | 0.81 | POLB (0.43) | CES2CES1MAPTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077895-A1 | Process for the preparation of strobilurin intermediates | WADITSCHATKA RUDOLF (CH) | 2004-04-22 | — | — | US | disclosed |
| US-6664422-B1 | Process for the preparation of strobilurin intermediates | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-16 | — | — | US | disclosed |
| EP-0984686-B1 | METHOD FOR COMBATING HARMFUL FUNGI | BASF AG (DE) | 2002-02-20 | — | — | EP | disclosed |
| EP-1137627-A1 | PROCESS FOR THE PREPARATION OF STROBILURIN INTERMEDIATES | Bayer Aktiengesellschaft (DE) | 2001-10-04 | — | — | EP | disclosed |
| US-6255352-B1 | TREATING FUNGI, PLANTS, SOIL OR SEEDS WITH DOSAGE OF A BISOXIME DERIVATIVE | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-03 | — | — | US | disclosed |
| WO-2000034229-A1 | PROCESS FOR THE PREPARATION OF STROBILURIN INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-06-15 | — | — | WO | disclosed |
| US-6063813-A | FUNGICIDES AND INSECTICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-16 | — | — | US | disclosed |
| EP-0984686-A1 | METHOD FOR COMBATING HARMFUL FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998053682-A1 | METHOD FOR COMBATING HARMFUL FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 1998-12-03 | — | — | WO | disclosed |
| EP-0077983-B1 | TRIAZINE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-04-29 | — | — | EP | disclosed |
| US-4616014-A | HYPOTENSIVE AGENTS, ANTICOAGULANTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-07 | — | — | US | disclosed |
| EP-0077983-A1 | Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-05-04 | — | — | EP | disclosed |
| US-4293552-A | Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-4160834-A | INSECTICIDES | ELI LILLY AND COMPANY (US) | 1979-07-10 | — | — | US | disclosed |
| US-4083977-A | Novel insecticidal 1-(substituted benzoyl)-3-(substituted pyrazinyl)ureas | ELI LILLY AND COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077895-A1 | Process for the preparation of strobilurin intermediates | TET1, CYP1B1, STS | CES2 1780/4885CES1 1221/4885MAPT 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.